Q3 2025 Nykode Therapeutics ASA Earnings Call Transcript
Key Points
- Nykode Therapeutics AS (VACBF) has a strong focus on its three core assets: abi-suva, VB10.NEO, and the Tolerance platform, each targeting significant medical needs.
- The company is well-capitalized with a cash runway extending into 2028, providing financial stability to reach key inflection points.
- Progress has been made in the Abili-T trial for abi-suva, with protocol submissions to UK and EMA authorities and a supply agreement with MSD for pembrolizumab.
- VB10.NEO has shown strong immune responses in clinical trials and has a competitive manufacturing process with a seven-week turnaround time.
- The Tolerance platform has demonstrated long-lasting therapeutic effects and the ability to modulate immune responses, positioning it as a potential best-in-class treatment for autoimmune diseases.
- Total revenue and other income decreased significantly from $665,000 in Q3 2024 to $118,000 in Q3 2025, primarily due to reduced revenue from Genentech and Regeneron.
- The company recorded a net loss of $3.7 million for the third quarter, although this is an improvement from the $9.7 million loss in the same period of 2024.
- There is uncertainty regarding the timing of clinical trial readouts, with the first interim data from the Abili-T trial expected in 2027, contingent on patient enrollment starting by summer 2026.
- The company faces a pending tax case, with a non-current receivable of $32.5 million, which could impact cash flow projections if not resolved favorably.
- Despite progress, the competitive landscape for individualized neoantigen therapies is intense, with multiple ongoing trials from peers that could influence market dynamics.
Greetings and welcome to the Nykode Therapeutics Q3 2025 financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's not my pleasure to turn the call over to CEO, Michael Engsig. Please go ahead, sir.
Thank you very much, Kevin. Also from my side, a very warm welcome to all participants at today's Q3 report. Just to remind everybody of our forward-looking statements. Assuming you're familiar with these such statements, we will, move ahead.
As usual, it's my pleasure to have, next to me here, Agnete Fredriksen, our Chief Scientific Officer, and Head of Business Development as well as Co-Founder, and Harald Gurvin, our Chief Financial Officer.
A quick recap on our company strategy which we announced in Q3 this year, which really demonstrates our focus on our three core assets, abi-suva, formerly known as VB10.16, which is our lead asset and we're taking into a randomized control trial in Phase 2 and first line head
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
